Corbus Pharmaceuticals Holdings, Inc. announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Companys Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Companys investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) developed in partnership with CSPC, and CRB-601, a TGF blocking monoclonal antibody targeting the integrin v8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Companys highly peripherally restricted CB1 inverse agonist for the treatment of obesity.His unique experience will prove invaluable as are about to initiate the US dose escalation study for CRB-701 this quarter while partners at CSPC are undertaking the dose expansion study in China.

The first-in-human data on CRB-701 in Nectin-4 positive tumors presented at ASCO-GU were encouraging, and the emerging clinical data suggests a differentiated PK and favorable safety profile for CRB-701 as compared to enfortumab vedotin, said Dr. Smethurst. The potential to deliver higher doses of a Nectin-4 ADC while keeping patients on treatment for longer due to an improved safety and tolerability profile is an attractive and impactful value proposition for both physicians and patients. I look forward to executing the clinical and regulatory strategy for CRB-701 in bladder cancer as well as in other Nectin-4 rich tumors and advancing the other assets in the Corbus pipeline to meaningful clinical and strategic milestones throughout 2024 and beyond.

Dr. Dominic Smethurst has over twenty years of experience working with various pharmaceutical and biotechnology companies, clinical research institutions, and the UKs National Health Service (NHS). He most recently served as CMO of Bicycle Therapeutics, where he helped advance Nectin-4 investigational drugs through early stage and into late-stage development. Previously, Dr. Smethurst worked as a consultant advising biopharma companies, providing guidance on clinical development strategies and licensing projects.

Prior to that, he served as CMO of Tusk Therapeutics, an immuno-oncology company acquired by Roche, where he oversaw development of antibodies targeting CD25 and CD137, among others. Previously, as Vice President Oncology and Global Therapeutic Area Lead at Icon, a global contract research organization, he executed clinical trials involving numerous novel cancer treatments, including CAR-T therapies. Prior to that, Dr. Smethurst held physician leadership roles at AstraZeneca, Amgen and Adaptimmune.

Dr. Smethurst is a member of both the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. He earned an MBChB with Distinction from Addenbrookes Clinical School Cambridge, as well as an MA from Christs College Cambridge. About Corbus Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways.

Corbus pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGF expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts.